Trials / Completed
CompletedNCT06711991
A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease
A Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of Single/Multiple Dose Escalation of TQC3927 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 40 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This project is the stage of dose escalation, is was divided into single and multiple dose clinical study, This is a multi-center, randomized, double-blind, placebo-controlled , study to the safety, tolerability and pharmacokinetic characteristics of TQC3927 powder for inhalation in Chronic Obstructive Pulmonary Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQC3927 powder for inhalation | TQC3927 is a targeted inhibitor |
| DRUG | TQC3927 powder for inhalation placebo | A placebo without drug substance. |
Timeline
- Start date
- 2025-02-11
- Primary completion
- 2025-08-11
- Completion
- 2025-08-11
- First posted
- 2024-12-02
- Last updated
- 2025-08-15
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06711991. Inclusion in this directory is not an endorsement.